Overview

Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

Status:
Unknown status
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This study intends to determine whether steroid withdrawal or calcineurin inhibitor withdrawal is superior for graft function and graft survival. Secondary endpoints for this study are: incidence of tumors and cardiovascular events. The primary objective: To assess if superior graft function (glomerular filtration rate (GFR) difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de novo kidney transplant patients treated with Myfortic-everolimus plus steroids compared to Myfortic-cyclosporine.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Antwerp
Collaborators:
Erasme University Hospital
Novartis Pharmaceuticals
Universitair Ziekenhuis Brussel
University Hospital of Liege
University Hospital, Ghent
University of Liege
Treatments:
Antibodies, Monoclonal
Basiliximab
Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Everolimus
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Sirolimus